the results of a combination chemotherapy trial ( melphalan , ccnu , vincristine , cyclophosphamide ) involving 28 patients with stage iii ( n = 21 ) or stage ii ( n = 7 ) multiple myeloma suggest a high response rate , with a mean 71 % malignant cell destruction in 78.5 % of the patients .
C0025241
melphalan
C0026764
multiple myeloma